TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12718385

Group type: COMPARATOR
Intervention: Doxorubicin (30 mg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (14 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 63
Study: 10900630

Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 32
Study: 9548208

Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg daily)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Captopril/Enalapril
Number of subjects: 28
Study: 1606094

Group type: EXPERIMENTAL
Intervention: 10-mg intravenous metoclopramide
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 42
Study: 6464702

Group type: EXPERIMENTAL
Intervention: Samples positive for pathogenic bacteria (Haemophilus, pneumococci)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Samples with nonpathogens
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Large mastoid air cell systems
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Destruction of cell walls
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Sclerosis
Number of subjects: 193
Study: 31164067

Group type: EXPERIMENTAL
Intervention: 60 hours of therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0 hours of therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 15 hours of therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 30 hours of therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: All dosages
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test
Number of subjects: 41
Study: 28326598

Group type: EXPERIMENTAL
Intervention: Compassion meditation (CM) group
Number of subjects: 59

Group type: COMPARATOR
Intervention: Support group
Number of subjects: 59
Study: 26890016

Group type: EXPERIMENTAL
Intervention: Sensory Barrage Stimulation (SBS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SBS
Number of subjects: 10

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 10
Study: 25194106

Group type: EXPERIMENTAL
Intervention: 540 mL bladder-filling protocol
Number of subjects: 110

Group type: COMPARATOR
Intervention: 1080 mL bladder-filling protocol
Number of subjects: 110
Study: 20385892

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 1 mg 3 times daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 16163745

Group type: EXPERIMENTAL
Intervention: Pain at baseline
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Depression at baseline
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Social support, physical disability, social functioning
Number of subjects: 318
Study: 11408832

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9741812

Group type: EXPERIMENTAL
Intervention: Custom-designed hardware unit allowing adjustable delay of data acquisition after stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Custom-designed software for fast analogue-to-digital conversion (ADC) during data acquisition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vickers Medical Mystro electromyograph
Number of subjects: 0
Study: 8035933

Group type: EXPERIMENTAL
Intervention: Entacapone (400 mg or 800 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Carbidopa (150 mg) plus placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbidopa (150 mg) plus entacapone (400 mg or 800 mg)
Number of subjects: 10
Study: 2564109

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (5-fluorouracil and mitomycin C with or without induction course of 5-fluorouracil, vincristine, cyclophosphamide, and methotrexate)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 411
Study: 4772727

Group type: EXPERIMENTAL
Intervention: Benzhexol (8 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anticholinergic withdrawal
Number of subjects: 0
Study: 29216779

Group type: EXPERIMENTAL
Intervention: Commercial mouthwash containing essential oils and ethyl lauroyl arginate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (21.6% hydro-alcohol solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control (sterile water)
Number of subjects: 0
Study: 27475733

Group type: EXPERIMENTAL
Intervention: Adjusted heparin regimen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional heparin regimen
Number of subjects: 60
Study: 24005444

Group type: EXPERIMENTAL
Intervention: PEP therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care (including physical exercise)
Number of subjects: 90
Study: 22386009

Group type: EXPERIMENTAL
Intervention: Planned nursing consultations
Number of subjects: 287

Group type: COMPARATOR
Intervention: Planned rheumatologist's consultations
Number of subjects: 287

Group type: COMPARATOR
Intervention: Shared care model without planned consultations
Number of subjects: 287
Study: 20150004

Group type: EXPERIMENTAL
Intervention: Nifedipine (n=30)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Losartan (n=33)
Number of subjects: 63
Study: 17971121

Group type: EXPERIMENTAL
Intervention: Two axial grooves added to the crown preparation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Recementation of crowns
Number of subjects: 30

Group type: COMPARATOR
Intervention: One axial groove added to the crown preparation
Number of subjects: 30
Study: 16045805

Group type: EXPERIMENTAL
Intervention: Internet-based search of randomised trials
Number of subjects: 31
Study: 12810695

Group type: EXPERIMENTAL
Intervention: High-dose bolus interleukin-2 (IL-2) at a dosage of 600,000 U/kg every 8 hours on days 1 to 5 and days 15 to 19 (maximum 28 doses)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High-dose bolus interleukin-2 (IL-2)
Number of subjects: 69
Study: 10579620

Group type: EXPERIMENTAL
Intervention: Cervical tenaculum placement during embryo transfer (ET)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No tenaculum placement during embryo transfer (ET)
Number of subjects: 10
Study: 8568910

Group type: EXPERIMENTAL
Intervention: Dietary sources of hydroquinone (arbutin and free HQ) from foods such as wheat products, pears, coffee, tea, red wine, and broccoli.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking four cigarettes in approximately 30 minutes.
Number of subjects: 0
Study: 1880721

Group type: EXPERIMENTAL
Intervention: High-fat meal (fed condition)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fasted condition (control)
Number of subjects: 12
Study: 7093095

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31072716

Group type: COMPARATOR
Intervention: CIS
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ASSA
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CSA
Number of subjects: 21
Study: 29924038

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pentax AWS (channeled blade-type videolaryngoscope)
Number of subjects: 21

Group type: COMPARATOR
Intervention: McGRATH videolaryngoscope (non-channeled blade type)
Number of subjects: 21
Study: 26911438

Group type: EXPERIMENTAL
Intervention: Smart Glove (SG) group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional intervention (CON) group
Number of subjects: 46
Study: 26464863

Group type: EXPERIMENTAL
Intervention: Rhubarb supplementation (350mg, thrice daily for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative management (Control)
Number of subjects: 0
Study: 22905352

Group type: EXPERIMENTAL
Intervention: Real acupuncture (n=34)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo needling (n=34)
Number of subjects: 68
Study: 20674901

Group type: EXPERIMENTAL
Intervention: Single intrauterine insemination (IUI)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Double intrauterine insemination (IUI)
Number of subjects: 160
Study: 17403173

Group type: EXPERIMENTAL
Intervention: Oral folic acid 10 mg 3 times a week immediately after every dialysis session
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Oral folic acid
Number of subjects: 186
Study: 15684203

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 8518

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 8518
Study: 11972407

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 9837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9837
Study: 10214599

Group type: EXPERIMENTAL
Intervention: Intervention video 'Telling the Story ... To Live is God's Will'
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control video 'Colorectal Cancer: The Cancer No One Talks About'
Number of subjects: 70

Group type: COMPARATOR
Intervention: Both groups (Intervention and Control)
Number of subjects: 70
Study: 7883120

Group type: EXPERIMENTAL
Intervention: Amino acid substitutions in hexokinase II among patients with NIDDM
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (97 subjects with normal glucose tolerance)
Number of subjects: 112
Study: 2095342

Group type: EXPERIMENTAL
Intervention: Salbutamol 100 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol 300 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All doses of Salbutamol
Number of subjects: 12
Study: 873029

Group type: EXPERIMENTAL
Intervention: Tetrabid-Organon (standard therapeutic doses)
Number of subjects: 12
Study: 31234844

Group type: EXPERIMENTAL
Intervention: Non-nitrogen-containing bisphosphonates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27815860

Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 57
Study: 25996468

Group type: EXPERIMENTAL
Intervention: Facial‐Oral Tract Therapy (F.O.T.T.)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Fibreoptic Endoscopic Evaluation of Swallowing (FEES)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 119
Study: 23216760

Group type: EXPERIMENTAL
Intervention: Blood flow-restricted (BFR) exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-intensity resistance exercise without BFR
Number of subjects: 9
Study: 21670398

Group type: EXPERIMENTAL
Intervention: LOW diet
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: HIGH diet
Number of subjects: 49
Study: 19367397

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 5,000 Units twice daily
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) enoxaparin 40 mg per day
Number of subjects: 1994

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1994
Study: 16492813

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 56
Study: 15334697

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ap‐237
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 70
Study: 11198726

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg once daily for 7 days)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Cephalexin (500 mg three times daily for 7 days)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 401

Group type: COMPARATOR
Intervention: Cephalexin
Number of subjects: 401
Study: 9129086

Group type: EXPERIMENTAL
Intervention: Zidovudine, zalcitabine, and saquinavir (exact dosages and duration not specified)
Number of subjects: 9
Study: 7960187

Group type: EXPERIMENTAL
Intervention: MAR IgG test result > 40%
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: Lower MAR IgG test results and majority of MAR IgA-positive patients
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: Higher MAR results
Number of subjects: 1189
Study: 2956200

Group type: EXPERIMENTAL
Intervention: 0.2 mg nifedipine administered intracoronarily before the first transluminal occlusion and again just before the second occlusion.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Solvent administered intracoronarily before the first transluminal occlusion and again just before the second occlusion.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.2 mg nifedipine administered intracoronarily just before the second transluminal occlusion.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine group during the second transluminal occlusion.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Solvent group during the second transluminal occlusion.
Number of subjects: 12
Study: 30586723

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 6979

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6979
Study: 30138233

Group type: EXPERIMENTAL
Intervention: Dopaminergic medication
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Individuals with PD
Number of subjects: 38
Study: 26111347

Group type: EXPERIMENTAL
Intervention: Treatment adherence enhancement intervention
Number of subjects: 138

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study: 23895391

Group type: EXPERIMENTAL
Intervention: Neutral cues indicating no specific temporal position of the comparison stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valid cues indicating the temporal position of the comparison stimulus
Number of subjects: 0
Study: 22464118

Group type: EXPERIMENTAL
Intervention: Yoga therapy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard prenatal care (Control)
Number of subjects: 84
Study: 20144174

Group type: EXPERIMENTAL
Intervention: Human placenta extract
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 17687341

Group type: EXPERIMENTAL
Intervention: Octreotide LAR combined with TMX (n=56)
Number of subjects: 109

Group type: COMPARATOR
Intervention: TMX alone (n=53; control group)
Number of subjects: 109
Study: 15841811

Group type: EXPERIMENTAL
Intervention: Preventive and operative regimen for mothers (n = 15)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Simple care and advice program for mothers (n = 12)
Number of subjects: 27
Study: 10878419

Group type: EXPERIMENTAL
Intervention: Caffeine (2.5 mg/kg once a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminophylline (1.25 mg/kg twice a day)
Number of subjects: 0
Study: 9280744

Group type: EXPERIMENTAL
Intervention: Adolescent mothers' newborns
Number of subjects: 430

Group type: COMPARATOR
Intervention: Adult mothers' newborns
Number of subjects: 430
Study: 1555424

Group type: EXPERIMENTAL
Intervention: Exosurf (5 ml/kg, intratracheal surfactant preparation)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Air (5 ml/kg, control group)
Number of subjects: 14
Study: 3925478

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.6 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Scopolamine 1.2 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0.0 mg)
Number of subjects: 12
Study: 3577645

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 31978403

Group type: EXPERIMENTAL
Intervention: Condition with retrieval practice
Number of subjects: 82

Group type: COMPARATOR
Intervention: Condition without retrieval practice
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease patients
Number of subjects: 82

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups (Alzheimer's Disease and healthy controls)
Number of subjects: 82
Study: 30910755

Group type: COMPARATOR
Intervention: Allogeneic bone graft
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Titanium mesh cage
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 57
Study: 28699570

Group type: EXPERIMENTAL
Intervention: Community-based approaches to vector control (pesticide-free dengue vector control)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard government dengue control (pesticide-dependent approaches)
Number of subjects: 150
Study: 25066869

Group type: EXPERIMENTAL
Intervention: Shock wave lithotripsy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Retrograde intrarenal surgery
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Miniperc
Number of subjects: 45
Study: 24211128

Group type: EXPERIMENTAL
Intervention: Arthroscopic repair
Number of subjects: 154

Group type: COMPARATOR
Intervention: Subacromial decompression
Number of subjects: 154
Study: 21166579

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 18454655

Group type: COMPARATOR
Intervention: SRP + placebo (N = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SRP + doxycycline (100 mg/day for 14 days) (N = 15)
Number of subjects: 30
Study: 16927289

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment for longer than 1 year
Number of subjects: 502
Study: 12614908

Group type: EXPERIMENTAL
Intervention: 200 mg levodopa
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10699690

Group type: COMPARATOR
Intervention: Nd‐YAG laser only
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combined Nd‐YAG laser/HDR brachytherapy
Number of subjects: 29
Study: 9061112

Group type: EXPERIMENTAL
Intervention: Bilateral maxillary nerve block with local anaesthetics (5-10 ml of bupivacaine 0.5% and lignocaine 2%)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bilateral maxillary nerve block with local anaesthetics
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 32
Study: 8448063

Group type: EXPERIMENTAL
Intervention: 400 mg carbamazepine liquid suspension
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional tablet formulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Controlled release tablet formulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3492378

Group type: EXPERIMENTAL
Intervention: 150 mg propyphenazone
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 300 mg propyphenazone
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 1000 mg acetylsalicylic acid (ASA)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 29786165

Group type: EXPERIMENTAL
Intervention: Robot‐PLIF
Number of subjects: 78

Group type: COMPARATOR
Intervention: Freehand‐PLIF
Number of subjects: 78
Study: 27020170

Group type: EXPERIMENTAL
Intervention: LA-EP2006
Number of subjects: 316

Group type: COMPARATOR
Intervention: Reference pegfilgrastim
Number of subjects: 316
Study: 24424705

Group type: EXPERIMENTAL
Intervention: Switching to aripiprazole
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Switching to ziprasidone
Number of subjects: 115
Study: 22441507

Group type: EXPERIMENTAL
Intervention: Intervention clinics (patients monitored by clinician order)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Random baseline sample
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 176
Study: 20459349

Group type: EXPERIMENTAL
Intervention: 0.25% DHEA
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: 0.5% DHEA
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: 1.0% DHEA
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control (placebo not specified)
Number of subjects: 218
Study: 18599271

Group type: EXPERIMENTAL
Intervention: Rapid IMF
Number of subjects: 120

Group type: COMPARATOR
Intervention: Eyelet wire ties (Control)
Number of subjects: 120
Study: 16898862

Group type: EXPERIMENTAL
Intervention: 3 oz (84 g) of almonds daily for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 6 oz (168 g) of almonds daily for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no almonds)
Number of subjects: 30
Study: 12830407

Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 104

Group type: COMPARATOR
Intervention: Protease inhibitors
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 104
Study: 10802368

Group type: EXPERIMENTAL
Intervention: Concomitant boost technique (CBT) radiation therapy, 46.8 Gy in 26 fractions with a concomitant boost of 18.2 Gy (0.7 Gy per fraction) to the gross disease, total dose 65 Gy in 26 fractions.
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional treatment technique (CTT) radiation therapy, 70.8 Gy in 38 fractions.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Concomitant boost technique (CBT) radiation therapy.
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional treatment technique (CTT) radiation therapy.
Number of subjects: 97